薯蓣膏治疗稳定期慢性阻塞性肺疾病患者的临床研究

doi:10.3760/cma.j.issn.1007-1245.2023.13.014

国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (13): 1837-1840.DOI: 10.3760/cma.j.issn.1007-1245.2023.13.014

薯蓣膏治疗稳定期慢性阻塞性肺疾病患者的临床研究

梁炳辉简小云林泽辉邹鹏江荣斌李家春王敬民詹伟杰

佛山市中医院肺病（呼吸）科，佛山　528000

收稿日期:2023-05-27 出版日期:2023-07-01 发布日期:2023-07-21
通讯作者: 简小云，Email：xyjxy200@126.com
基金资助:
广东省中医药局科研项目资助课题（20201341）

Clinical study of dioscorea glue in the treatment of stable chronic obstructive pulmonary disease

Liang Binghui, Jian Xiaoyun, Lin Zehui, Zou Peng, Jiang Rongbin, Li Jiachun, Wang Jingmin, Zhan Weijie

Pulmonary (Respiratory) Department, Foshan Hospital of Traditional Chinese Medicine, Foshan 528000, China

Received:2023-05-27 Online:2023-07-01 Published:2023-07-21
Contact: Jian Xiaoyun, Email: xyjxy200@126.com
Supported by:
Research Project of Guangdong Provincial Bureau of Traditional Chinese Medicine (20201341)

摘要/Abstract

摘要：

目的　观察薯蓣膏治疗稳定期慢性阻塞性肺疾病（COPD）患者的临床疗效。方法　本文为前瞻性随机对照试验。选取2020年11月至2022年3月佛山市中医院呼吸内科门诊就诊的稳定期COPD肺脾气虚患者120例为研究对象，采用随机数字表法分为两组，各60例。治疗组男42例，女18例，年龄（65.77±5.59）岁；对照组男40例，女20例，年龄（64.68±4.92）岁。对照组给予常规西医治疗，治疗组在常规西医治疗基础上加服薯蓣膏，疗程6个月。观察两组患者治疗前及治疗后3个月、6个月的肿瘤坏死因子-α（TNF-α）、CD3⁺、CD4⁺、白蛋白（ALB）、BODE指数、急性加重次数指标的变化。采用t检验、χ²检验。结果　治疗后3个月、6个月，治疗组TNF-α指标［（5.89±1.14）ng/L、（5.55±1.21）ng/L］均低于照组［（6.79±1.11）ng/L、（6.66±1.19）ng/L］，CD3⁺［（56.61±5.49）%、（59.89±5.01）%］、CD4⁺指标［（34.56±4.49）%、（35.50±4.29）%］均高于对照组［（53.64±5.68）%、（53.28±5.05）%、（30.82±4.20）%、（30.79±4.20）%］，差异均有统计学意义（均P<0.05）。治疗后6个月，治疗组ALB指标［（35.89±0.64）g/L］高于对照组［（29.14±0.64）g/L］，BODE指数［（1.63±0.95）分］、急性加重次数［（1.30±0.17）次］均低于对照组［（2.18±1.12）分、（1.62±0.21）次］，差异均有统计学意义（均P<0.05）。结论　加服薯蓣膏治疗稳定期COPD肺脾气虚证患者，可减轻患者症状，抑制炎症因子表达，调节机体免疫功能，改善营养状态，从而提高患者生活质量，减少急性加重风险。

关键词:

慢性阻塞性肺疾病, 稳定期, 肺脾气虚, 薯蓣膏

Abstract:

Objective　To evaluate the clinical efficacy of dioscorea glue in the treatment of stable chronic obstructive pulmonary disease (COPD). Methods　This was a prospective randomized controlled trial. From November 2020 to March 2022, a total of 120 patients with stable COPD and qi deficiency of lung and spleen in Department of Respiratory Medicine of Foshan Hospital of Traditional Chinese Medicine were divided into a treatment group (60 cases) and a control group (60 cases) by the random number table method. In the treatment group, there were 42 males and 18 females, aged (65.77±5.59) years. In the control group, there were 40 males and 20 females, aged (64.68±4.92) years. The control group was given conventional western medicine treatment, and the treatment group was given dioscorea glue on the basis of conventional western medicine treatment for 6 months. The changes of tumor necrosis faction-α (TNF-α), CD3⁺, CD4⁺, albumin (ALB), BODE index, and number of acute exacerbations before treatment and 3 and 6 months after treatment were observed in the two groups. t test and χ² test were used. Results　Three and six months after treatment, the TNF-α indexes [(5.89±1.14) ng/L and (5.55±1.21) ng/L] in the treatment group were lower than those in the control group [(6.79±1.11) ng/L and (6.66±1.19) ng/L], and the CD3⁺ [(56.61±5.49)% and (59.89±5.01)%] and CD4⁺ indexes [(34.56±4.49)% and (35.50±4.29)%] were higher than those in the control group [(53.64±5.68)%, (53.28±5.05)%, (30.82±4.20)%, and (30.79±4.20)%], with statistically significant differences (all P<0.05). Six months after treatment, the ALB index [(35.89±0.64) g/L] in the treatment group was higher than that in the control group [(29.14±0.64) g/L], and the BODE index [(1.63±0.95) points] and the number of acute exacerbations [(1.30±0.17) times] were lower than those of the control group [(2.18±1.12) points and (1.62±0.21) times], with statistically significant differences (all P<0.05). Conclusion　Dioscorea glue combined with bronchodilator inhalant is effective in the treatment of stable COPD patients with qi deficiency of lung and spleen, which can eliminate the inflammation, regulate the immune function, improve the clinical symptoms and nutritional status, reduce the number of acute exacerbations, and improve the quality of life.

Key words:

COPD, Stable phase, Qi deficiency of lung and spleen, Dioscorea glue

梁炳辉简小云林泽辉邹鹏江荣斌李家春王敬民詹伟杰.

薯蓣膏治疗稳定期慢性阻塞性肺疾病患者的临床研究 [J]. 国际医药卫生导报, 2023, 29(13): 1837-1840.

Liang Binghui, Jian Xiaoyun, Lin Zehui, Zou Peng, Jiang Rongbin, Li Jiachun, Wang Jingmin, Zhan Weijie.

Clinical study of dioscorea glue in the treatment of stable chronic obstructive pulmonary disease [J]. International Medicine and Health Guidance News, 2023, 29(13): 1837-1840.

参考文献

[1] Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study[J].Lancet,2018,391(10131):1706-1717.DOI:10.1016/S0140-6736(18)30841-9.
[2] 夏婉飞,黄国华,古辉,李雪平,陈少立,刘兆男.噻托溴铵/奥达特罗治疗C、D组慢性阻塞性肺疾病稳定期患者的效果[J].广州医药,2023,54(4):100-103,114.DOI:10.3969/j.issn.1000-8535.2023.04.018.
[3] 赵丽.多索茶碱联合甲强龙治疗急性加重期COPD患者的疗效及对血清炎症因子水平的影响[J].哈尔滨医药,2023,43(2):5-7.DOI:10.3969/j.issn.1001-8131.2023.02.002.
[4] D'Anna SE, Maniscalco M, Cappello F, et al. Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease[J].Ann Med,2021,53(1):135-150.DOI:10.1080/07853890.2020.1831050.
[5] Agusti A, Fabbri LM, Singh D, et al. Inhaled corticosteroids in COPD: friend or foe?[J].Eur Respir J,2018,52(6):1801219.DOI:10.1183/13993003.01219-2018.
[6] Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease[J].Lancet,2004,364(9435):709-721.DOI:10.1016/S0140-6736(04)16900-6.
[7] 李建生,余学庆,王明航,等. 中医治疗慢性阻塞性肺疾病研究的策略与实践[J]. 中华中医药杂志,2012,27(6):1607-1614.
[8] 陈亚红. 2018年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J/CD]. 中国医学前沿杂志(电子版),2017,9(12):15-22.DOI:10.12037/YXQY.2017.12-05.
[9] 李建生,李素云,余学庆.慢性阻塞性肺疾病中医诊疗指南(2011版)[J].中医杂志,2012,53(1):80-84.DOI:10.13288/j.11-2166/r.2012.01.011.
[10] 马玉玲. 慢性阻塞性肺疾病缓解期中医辨证论治的文献研究[D]. 广州:暨南大学,2015.
[11] 王鹏,王韶华. 慢性阻塞性肺疾病稳定期中医证候及用药规律文献分析[J]. 临床医学研究与实践,2020,5(27):149-150,153.DOI:10.19347/j.cnki.2096-1413.202027060.
[12] 吕俊,何晓凤,余小萍.慢性阻塞性肺疾病稳定期中医药治疗研究进展[J].中医临床研究,2018,10(9):61-64.
[13] 龚年金,兰智慧,朱伟,等. 浅析健脾温肾法在慢性阻塞性肺疾病治疗中的运用[J]. 中华中医药杂志,2018,33(4):1397-1400.
[14] 李梅琴,邓尔禄. 培本补肺散治疗肺肾气虚型慢性阻塞性肺病的临床效果分析[J]. 中国中医基础医学杂志,2018,24(3):361-363,381.DOI:10.19945/j.cnki.issn.1006-3250.2018. 03.024
[15] 郭文慧,原景,张炜. 益气活血化痰方治疗慢性阻塞性肺疾病稳定期疗效研究[J]. 陕西中医,2021,42(6):721-723,738. DOI:10.3969/j.issn.1000-7369.2021.06.010.
[16] 江雁琼,伍慧妍,文艳琼. 慢阻肺急性加重期感染病原菌分布与机体免疫功能检测及其临床意义[J]. 中国病原生物学杂志,2019,14(2):213-216.DOI:10.13350/j.cjpb.190219.
[17] 黄奕江,冯夏,郑万川.慢性阻塞性肺病患者免疫功能的研究[J].临床内科杂志,1997(1):30-31.
[18] 程志清. 膏方的临床应用: 全国膏方抗癌专家委员会年会、全国膏方医学专业委员会2016年年会暨华东地区全国优秀中医临床人才专家座谈会[C].中国浙江杭州,2016.
[19] Khalaf RM, Lea SR, Metcalfe HJ, et al. Mechanisms of corticosteroid insensitivity in COPD alveolar macrophages exposed to NTHi[J].Respir Res,2017,18(1):61.DOI:10.1186/s12931-017-0539-4.
[20] 于惠青,于俊生.对«金匮要略»薯蓣丸方证的理解[J].中国中医基础医学杂志,2013,19(7):817-818.DOI:10.19945/j.cnki.issn.1006-3250.2013.07.042.
[21] 王东军,张颖,祖立斌,等. 薯蓣丸方证探析与临床应用[J]. 浙江中医杂志,2022,57(9):689-690.DOI:10.3969/j.issn.0411-8421.2022.09.036.
[22] 刘迅,周月,彭岚玉,等. 薯蓣丸药理作用及临床应用研究概况[J]. 中国中医药信息杂志,2022,29(5):153-156.DOI:10.19879/j.cnki.1005-5304.202110139.
[23] 邓哲.薯蓣丸抑制HIF-1α改善肝癌微环境缺氧与免疫逃逸的机制研究[D].长沙:湖南中医药大学,2020.DOI:10.27138/d.cnki.ghuzc.2020.000316.
[24] 林明峰.治未病理论下薯蓣丸膏方治疗肺脾气虚型C0PD稳定期临床疗效研究[D].北京:北京中医药大学,2020.DOI:10.26973/d.cnki.gbjzu.2020.000411.
[25] 蔡美,周衡.«金匮»薯蓣丸对小鼠免疫功能的影响[J].湖南中医药导报,1997(6):31-32,34.DOI:10.13862/j.cnki.cn43-1446/r.1997.06.022.
[26] Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease[J].N Engl J Med,2004,350(10):1005-1012.DOI:10.1056/NEJMoa021322.
[27] Moll M, Qiao D, Regan EA, et al. Machine learning and prediction of all-cause mortality in COPD[J].Chest,2020,158(3):952-964.DOI:10.1016/j.chest.2020.02.079.
[28] Soler-Cataluña JJ, Martínez-García MA, Sánchez LS, et al. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients[J].Respir Med,2009,103(5):692-699.DOI:10.1016/j.rmed.2008. 12.005.

薯蓣膏治疗稳定期慢性阻塞性肺疾病患者的临床研究

Clinical study of dioscorea glue in the treatment of stable chronic obstructive pulmonary disease

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics